AUS
NZ
UK
CA
USA
IND
Highlights:
- Positive Clinical Trial Results: Merck's clesrovimab reduces RSV-related hospitalizations by over 84% in a mid-to-late-stage trial.
- No Major Side Effects: The treatment showed no significant adverse effects while reducing respiratory infections requiring medical care by 60%.
- Regulatory Path Forward: Merck plans to seek regulatory approval, targeting a launch for infants by the 2025-2026 RSV season.
Merck & Co Inc (NYSE:MRK) announced that its experimental treatment for respiratory syncytial virus (RSV), clesrovimab, has delivered encouraging outcomes in a key mid-to-late-stage clinical trial. The treatment, which is aimed at protecting infants from RSV-related hospitalizations, represents a significant step toward the company’s goal of seeking regulatory approval.
RSV is a major cause of hospitalizations in newborns and leads to hundreds of infant deaths annually. The trial showed that clesrovimab reduced RSV-related hospitalizations by more than 84% and lowered respiratory infections requiring medical attention by over 60%. Importantly, no major side effects were observed in the trial, further highlighting the treatment’s potential safety and effectiveness.
Merck plans to engage with regulators to advance the approval process, aiming to introduce clesrovimab by the 2025-2026 RSV season. If successful, the treatment will enter a competitive market, currently dominated by similar RSV treatments from companies like Sanofi and AstraZeneca.
Merck’s clesrovimab could mark a breakthrough in protecting vulnerable infants from a virus that has historically been difficult to manage. The company's pursuit of regulatory approval aligns with its broader commitment to addressing unmet medical needs in pediatric health.
